Pur­due shells out a lit­tle more cash for a non-prof­it biotech work­ing on nalox­one OTC nasal spray

In the lat­est in­stall­ment of the Pur­due Phar­ma and opi­oid epi­dem­ic saga, the heav­i­ly sanc­tioned phar­ma com­pa­ny is shelling out a lit­tle more mon­ey — though not that much com­pared to the mul­ti-bil­lion dol­lar set­tle­ment it has reached. This time, it’s for $11 mil­lion — and the cash is go­ing to a small-time biotech for an opi­oid over­dose treat­ment drug.

The phar­ma an­nounced the newest de­vel­op­ment re­cent­ly in­to tiny biotech Harm Re­duc­tion Ther­a­peu­tics (HRT), a 501c3 non-prof­it found­ed in 2017. The com­pa­ny’s sole fo­cus is on get­ting an OTC nasal spray for nalox­one ap­proved and avail­able on the mar­ket over the counter at “sub­stan­tial­ly low­er re­tail cost,” com­pared to oth­er nalox­one prod­ucts on the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER